We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-9.41%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$982M
AUM Growth
+$21.4M
Cap. Flow
+$184M
Cap. Flow %
18.72%
Top 10 Hldgs %
37.6%
Holding
143
New
43
Increased
40
Reduced
5
Closed
15

Top Buys

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$29.1M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$19.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$15.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$15.4M
5
TDOC icon
Teladoc Health
TDOC
+$12.2M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$24.5M
2
MOR
MorphoSys AG American Depositary Shares
MOR
+$14.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.44M
4
NTLA icon
Intellia Therapeutics
NTLA
+$5.5M
5
BLUE
bluebird bio
BLUE
+$3.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.92%
2 Technology 1.53%
3 Real Estate 0.71%
4 Communication Services 0.66%
5 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOLN
126
Molecular Partners
MOLN
$18.1K ﹤0.01%
2,500
-97,500
-98% -$456K
LVTX
127
DELISTED
LAVA Therapeutics
LVTX
$9.2K ﹤0.01%
+5,109
New +$13.5K
ABOS icon
128
Acumen Pharmaceuticals
ABOS
$176M
– –
-246,895
Closed -$1,000K
AMRN
129
Amarin Corp
AMRN
$303M
– –
-125,000
Closed -$2.23M
BLUE
130
DELISTED
bluebird bio
BLUE
– –
-125,000
Closed -$3.2M
IFRX icon
131
InflaRx
IFRX
$271M
– –
-769,065
Closed -$1.18M
KZR
132
DELISTED
Kezar Life Sciences
KZR
– –
-68,894
Closed -$621K
DFTX
133
Definium Therapeutics
DFTX
$6.12B
– –
-300,000
Closed -$2.82M
NTLA icon
134
Intellia Therapeutics
NTLA
$1.67B
– –
-200,000
Closed -$5.5M
QURE icon
135
uniQure
QURE
$3.22B
– –
-133,921
Closed -$696K
FLG
136
Flagstar Bank National Association
FLG
$5.82B
– –
-202,200
Closed -$1.95M
EQC
137
DELISTED
Equity Commonwealth
EQC
– –
-165,261
Closed -$3.12M
ENZ
138
DELISTED
Enzo Biochem, Inc.
ENZ
– –
-1,260,013
Closed -$1.6M
MOR
139
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-800,705
Closed -$14.5M
DCPH
140
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-600,000
Closed -$9.44M
KNTE
141
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-977,626
Closed -$2.6M
INBX
142
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-700,000
Closed -$24.5M
2 3 4 5
6

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Tang Capital Management held 143 positions worth $982M, up 2.2% from $960M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tang Capital Management deployed $184M of net new capital in Q2 2024, opening 43 new positions and adding to 40 existing holdings. Its largest new stake was Dynavax Technologies: 2,500,000 shares worth $28.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Technology and Real Estate.

On the sell side, the largest reduction was Quince Therapeutics, an estimated $1.31M trimmed.

  • Tang Capital Management's largest Q2 2024 buy was Dynavax Technologies: 2,500,000 shares worth $28.1M.
  • Tang Capital Management added most to ANI Pharmaceuticals in Q2 2024, an estimated $19.5M increase.
  • Tang Capital Management's biggest Q2 2024 reduction was Quince Therapeutics, cutting an estimated $1.31M.
  • Tang Capital Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $24.5M.
  • Tang Capital Management's ten largest holdings make up 38% of its $982M portfolio in Q2 2024.
  • Tang Capital Management opened 43 new positions and closed 15 in Q2 2024.
  • Tang Capital Management's portfolio value rose 2.2% quarter-over-quarter to $982M.

Based on Tang Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.